FDA Approved: SPEVIGO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SPEVIGO (spesolimab-sbzo) to update its labeling following initial approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• SPEVIGO (SPESOLIMAB-SBZO)

Snippet

SUPPL AP for SPEVIGO (SPESOLIMAB-SBZO)